TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07365995: A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Sponsor: BioNTech SE · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 736 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$19,681,200

Rescue Site Savings

+$12,989,592

Unlock Full NCT07365995 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07365995 Rescue Dossier →